The delay phase 3 mainly cause by lack of the supplier compound chemically-derived thapsigargin. This this is the biggest problem to why they can't move to phase3.
In order to find a solution they partnership with Phyton Biotech. Inspyr Therapeutics partnership with Phyton Biotech has begun development program converting the Thapsia garganic plant into thapsigargin.
Inspyr Therapeutics has a patented technology platform utilizing thapsigargin for its prodrug mipsagargin G-202
Phyton Biotech they work with a lot of big Pharma players and this company is an expert in the field. IMO: A possible partnership/buyout could be in the making through Phyton Biotech.